Concepedia

Gary Albert

GA

Statistics

Publications

19

Citations

3.1K

H-Index

18

Active since

1974

Affiliations

Novavax (United States)(Current)

University of Maryland, Baltimore

South African Medical Research Council

University of the Witwatersrand

University of Pretoria

Gary Albert is an author at Novavax (United States) specializing in veterinary medicine, immunization, and vaccination.

ORCID

Publications per year

1974–2023

19

Publications

19

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech, Gary Albert, Iksung Cho et al. · New England Journal of Medicine · 2020 · 1.2K citations · Full text

, , +17

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Vivek Shinde, Sutika Bhikha, Zaheer Hoosain et al. · New England Journal of Medicine · 2021 · 662 citations · Full text

, , +17

RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus

Martin R. Zamora, Marie Budev, Mark W. Rolfe et al. · American Journal of Respiratory and Critical Care Medicine · 2010 · 208 citations

, , +16

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

Christian Manegold, Donald Gravenor, Donald Woytowitz et al. · Journal of Clinical Oncology · 2008 · 169 citations · Full text

, , +14

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial

Neil Formica, Raburn M. Mallory, Gary Albert et al. · PLoS Medicine · 2021 · 113 citations · Full text

, , +17

1–5 of 19